Relaxin as a cardiovascular drug: A promise kept

Current Drug Safety

Volumn 6, Issue 5, 2011, Pages 324-328

  Bani, Daniele ^a   Bigazzi, Mario ^b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b Prosperius Institute   (Italy)

Author keywords

Cardiovascular disease; Heart failure; Oral delivery; Relaxin

Indexed keywords

CALCITONIN; CARDIOVASCULAR AGENT; ENKEPHALIN; ENZYME; ENZYME INHIBITOR; GLUCAGON; GROWTH HORMONE; INSULIN; INTERFERON; PLACEBO; RECOMBINANT RELAXIN; UNCLASSIFIED DRUG; VITALAXIN PLUS;

ACUTE HEART FAILURE; ACUTE HEART INFARCTION; CELL DIFFERENTIATION; CELL GROWTH; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; CORONARY BLOOD VESSEL; DIABETES MELLITUS; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG USE; DYSPNEA; HEART AFTERLOAD; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE CELL; HUMAN; HYPERTENSION; INTERMITTENT CLAUDICATION; MULTICENTER STUDY (TOPIC); NONHUMAN; PATIENT COMPLIANCE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHASE 2 CLINICAL TRIAL (TOPIC); PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMBINANT DNA TECHNOLOGY; REVIEW; SECONDARY PREVENTION;

ANIMALS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CELL DIFFERENTIATION; CLINICAL TRIALS AS TOPIC; DNA, RECOMBINANT; HUMANS; MYOCYTES, CARDIAC; RELAXIN;

EID: 84855828809     PISSN: 15748863     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488611798918719     Document Type: Review

References (61)

1. Schwabe C, Steinetz B, Weiss G, et al. Relaxin. Recent Prog Horm Res 1978; 34: 123-211.
2. Bathgate RA, Samuel CS, Burazin TC, Gundlach AL, Tregear GW. Relaxin: new peptides, receptors and novel actions. Trends Endocrinol Metab 2003; 14: 207-13.
3. Samuel CS, Du XJ, Bathgate RAD, Summers RJ. Relaxin' the stiffened heart and arteries: the therapeutic potential for relaxin in the treatment of cardiovascular disease. Pharm Ther 2006; 112: 529-52.
4. Ivell R, Hunt N, Khan-Dawood F, Dawood MY. Expression of the human relaxin gene in the corpus luteum of the menstrual cycle and in the prostate. Mol Cell Endocrinol 1989; 66: 251-5.
5. O'Byrne EM, Carriere BT, Sorensen L, Segaloff A, Schwabe C, Steinetz BG. Plasma immunoreactive relaxin levels in pregnant and nonpregnant women. J Clin Endocrinol Metab 1978; 47: 1106-10.
6. Eddie LW, Bell RJ, Lester A, et al. Radioimmunoassay of relaxin in pregnancy with an analogue of human relaxin. Lancet 1986; 8494: 1344-6.
7. Hsu SY, Nakabayashi K, Nishi S, et al. Activation of orphan receptors by the hormone relaxin. Science 2002; 295: 671-4.
8. Bathgate RA, Ivell R, Sanborn BM, Sherwood OD, Summers RJ. International Union of Pharmacology LVII: recommendations for the nomenclature of receptors for relaxin family peptides. Pharmacol Rev 2006; 58: 7-31.
9. van der Westhuizen ET, Halls ML, Samuel CS, et al. Relaxin family peptide receptors-from orphans to therapeutic targets. Drug Discov Today 2008; 13: 640-51.
10. Baccari MC, Bani D. Relaxin and nitric oxide signalling. Curr Protein Pept Sci 2008; 9: 638-45.
11. Bani D. Relaxin: a pleiotropic hormone. Gen Pharmacol 1997; 28: 13-22.
12. Sherwood OD. Relaxin's physiological roles and other diverse actions. Endocr Rev 2004; 25: 205-34.
13. Baccari MC, Calamai F. Relaxin: new functions for an old peptide. Curr Protein Pept Sci 2004; 5: 9-18.
14. Dschietzig T, Bartsch C, Baumann G, Stangl K. Relaxin-a pleiotropic hormone and its emerging role for experimental and clinical therapeutics. Pharmacol Ther 2006; 112: 38-56.
15. Chan LJ, Hossain MA, Samuel CS, Separovic F, Wade JD. The relaxin peptide family--structure, function and clinical applications. Protein Pept Lett 2011; 18: 220-9.
16. Bani D, Yue SK, Bigazzi M. Clinical profile of relaxin, a possible new drug for human use. Curr Drug Saf 2009; 4: 238-49.
17. Canova-Davis E, Kessler TJ, Lee PJ, et al. Use of recombinant DNA derived human relaxin to probe the structure of the native protein. Biochemistry 1991; 30: 6006-13.
18. Conrad KP. Maternal vasodilation in pregnancy: the emerging role of relaxin. Am J Physiol Regul Integr Comp Physiol 2011; 301: R267-75.
19. Bani D, Bigazzi M. Clinical aspects and therapeutic perspectives of relaxin. Curr Med Chem-Immunol Endocr Metab Agents (CMCIEMA) 2005; 5: 403-10.
20. Nistri S, Bigazzi M, Bani D. Relaxin as a cardiovascular hormone. Physiology, pathophysiology and therapeutic promises. Cardiovasc Hematol Agents Med Chem (CHA-MC) 2007; 5: 101-8.
21. Samuel CS, Hewitson TD, Unemori EN, Tang ML. Drugs of the future: the hormone relaxin. Cell Mol Life Sci 2007; 64: 1539-57.
22. Bani D. Relaxin as a natural agent for vascular health. Vasc Health Risk Manag 2008; 4: 515-24.
23. Du XJ, Bathgate RA, Samuel CS, Dart AM, Summers RJ. Cardiovascular effects of relaxin: from basic science to clinical therapy. Nat Rev Cardiol 2010; 7: 48-58.
24. Conrad KP. Unveiling the vasodilatory actions and mechanisms of relaxin. Hypertension 2010; 56: 2-9.
25. Teichman SL, Unemori E, Dschietzig T, et al. Relaxin, a pleiotropic vasodilator for the treatment of heart failure. Heart Fail Rev 2009; 14: 321-9.
26. Taylor MJ, Clark CL. Evidence for a novel source of relaxin: atrial cardiocytes. J Endocrinol 1994; 143: R5-8.
27. Dschietzig T, Richter C, Bartsch C, et al. The pregnancy hormone relaxin is a player in human heart failure. FASEB J. 2001; 15: 2187-95.
28. Fisher C, Berry C, Blue L, Morton JJ, McMurray J. N-terminal pro B type natriuretic peptide, but not the new putative cardiac hormone relaxin, predicts prognosis in patients with chronic heart failure. Heart 2003; 89: 879-81.
29. Osheroff PL, Ho W. Expression of relaxin mRNA and relaxin receptors in postnatal and adult rat brain and hearts. J Biol Chem 1993; 268: 15193-9.
30. Kompa AR, Samuel CS, Summers RJ. Inotropic responses to human gene 2 (B29) relaxin in a rat model of myocardial infarction (MI): effect of pertussis toxin. Br J Pharmacol 2002; 137: 710-8.
31. Bani Sacchi T, Bigazzi M, Bani D, Mannaioni PF, Masini E. Relaxininduced increased coronary flow through stimulation of nitric oxide production. Br J Pharmacol 1995; 116: 1589-94.
32. Masini E, Bani D, Bello MG, Bigazzi M, Mannaioni PF, Bani Sacchi T. Relaxin counteracts myocardial damage induced by ischemiareperfusion in isolated guinea pig hearts: evidence for an involvement of nitric oxide. Endocrinology 1997; 138: 4713-20.
33. McGuane JT, Danielson LA, Debrah JE, Rubin JP, Novak J, Conrad KP. Angiogenic growth factors are new and essential players in the sustained relaxin vasodilatory pathway in rodents and humans. Hypertension 2011; 57: 1151-60.
34. Samuel CS, Lekgabe ED, Mookerjee I. The effects of relaxin on extracellular matrix remodeling in health and fibrotic disease. Adv Exp Med Biol 2007; 612: 88-103.
35. Du XJ, Samuel CS, Gao XM, Zhao L, Parry LJ, Tregear GW. Increased myocardial collagen and ventricular diastolic dysfunction in relaxin deficient mice: a gender-specific phenotype. Cardiovasc Res 2003; 57: 395-404.
36. Samuel CS, Unemori EN, Mookerjee I, et al. Relaxin modulates cardiac fibroblast proliferation, differentiation, and collagen production and reverses cardiac fibrosis in vivo. Endocrinology 2004; 145: 4125-33.
37. Lekgabe ED, Kiriazis H, Zhao C, et al. Relaxin reverses cardiac and renal fibrosis in spontaneously hypertensive rats. Hypertension 2005; 46: 412-8.
38. Xu Q, Chakravorty A, Bathgate RA, Dart AM, Du XJ. Relaxin therapy reverses large artery remodeling and improves arterial compliance in senescent spontaneously hypertensive rats. Hypertension 2010; 55: 1260-6.
39. Nistri S, Pini A, Sassoli C, et al. Relaxin promotes growth and maturation of mouse neonatal cardiomyocytes in vitro: clues for cardiac regeneration. J Cell Mol Med. 2011 May 6. (Epub ahead of print) doi: 10.1111/j.1582-4934.2011.01328.x
40. Gheorghiade M, Pang PS. Acute heart failure syndromes. J Am Coll Cardiol 2009; 53: 557-73.
41. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008; 10: 933-89.
42. Teerlink JR. Overview of randomised clinical trials in acute heart failure syndromes. Am J Cardiol 2005; 96: 59G-67G.
43. St-Louis J, Massicotte G. Chronic decrease of blood pressure by rat relaxin in spontaneously hypertensive rats. Life Sci 1985; 37: 1351-7.
44. Massicotte G, Parent A, St-Louis J. Blunted responses to vasoconstrictors in mesenteric vasculature but not in portal vein of spontaneously hypertensive rats treated with relaxin. Proc Soc Exp Biol Med 1989; 190: 254-9.
45. Debrah DO, Conrad KP, Jeyabalan A, Danielson LA, Shroff SG. Relaxin increases cardiac output and reduces systemic arterial load in hypertensive rats. Hypertension 2005; 46: 745-50.
46. Chen SA, Perlman AJ, Spanski N, et al. The pharmacokinetics of recombinant human relaxin in nonpregnant women after intravenous, intravaginal, and intracervical administration. Pharm Res 1993; 10: 834-8.
47. Dschietzig T, Teichman S, Unemori E, et al. Intravenous recombinant human relaxin in compensated heart failure: a safety, tolerability, and pharmacodynamic trial. J Card Fail 2009; 15: 182-90.
48. Teerlink JR, Metra M, Felker GM, et al. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet 2009; 373: 1429-39.
49. Seibold JR, Clements PJ, Furst DE, et al. Safety and pharmacokinetics of recombinant human relaxin in systemic sclerosis. J Rheumatol 1998; 25: 302-7.
50. Seibold JR, Korn JH, Simms R, et al. Recombinant human relaxin in the treatment of scleroderma. A randomised, double-blind, placebocontrolled trial. Ann Intern Med 2000; 132: 871-9.
51. Casten GG, Gilmore HR, Houghton FE, Samuels SS. A new approach to the management of obliterative peripheral arterial disease. Angiology 1960; 11: 408-14.
52. Dschietzig T, Stangl K. Relaxin: a pregnancy hormone as central player of body fluid and circulation homeostasis. Cell Mol Life Sci 2003; 60: 688-700.
53. Heinemann L, Jacques Y. Oral insulin and buccal insulin: a critical reappraisal. J Diabetes Sci Technol 2009; 3: 568-84.
54. Antunes F, Andrade F, Ferreira D, van de Weert M, Nielsen HM, Sarmento B. Models to Predict Intestinal Absorption of Therapeutic Peptides and Proteins. Curr Drug Metab 2011; Sep 20. [Epub ahead of print].
55. Carino GP, Mathiowitz E. Oral insulin delivery. Adv Drug Deliv Rev 1999; 35: 249-57.
56. Hossain MA, Rosengren KJ, Samuel CS, et al. The minimal active structure of human relaxin-2. J Biol Chem 2011; 286: 37555-65.
57. Milia P, Caserio M, Rastelli TF, Sonaglia F, Bigazzi M. Efficacy of relaxin (porcine relaxin) on funcional recovery of post stroke patients: a case control study. J Neurol Sci 2009; 285(suppl. 1): S180.
58. Bani D, Nistri S, Cinci L, et al. A novel, simple bioactivity assay for relaxin based on inhibition of platelet aggregation. Regul Peptides 2007; 144: 10-6.
59. Halls ML, Bond CP, Sudo S, et al. Multiple binding sites revealed by interaction of relaxin family peptides with native and chimeric relaxin family peptide receptors 1 and 2 (LGR7 and LGR8). J Pharmacol Exp Ther 2005; 313: 677-87.
60. Pini A, Shemesh R, Samuel CS, et al. Prevention of bleomycin induced pulmonary fibrosis by a novel anti-fibrotic peptide with relaxin like activity. J Pharmacol Exp Ther 2010; 335: 589-99.
61. Bennett RG. Relaxin and its role in the development and treatment of fibrosis. Transl Res 2009; 154: 1-6.